Nippon Shinyaku (NPNKF)

Overall impact
B (74)

Commentary

Nippon Shinyaku is a strong overall performer. With a 'B' rating of 73.8 for overall impact (87th percentile compared to all companies), Nippon Shinyaku ranks 35th out of 154 industry peers, behind Benitec Biopharma, Aquinox Pharmaceuticals, China SXT Pharmaceuticals and 31 others, and ahead of Adamis Pharmaceuticals, Assertio Therapeutics, Evolus and 116 others. On top material causes for Nippon Shinyaku's industry (Pharmaceuticals & Biotech), Nippon Shinyaku performs well in Access to Affordable Healthcare (91.0 score), Sustainable Use of Water (88.7), Disaster Readiness and Effective Aid (84.5) and 2 other causes where it received an 'A' score and performs poorly in Child and Maternal Health (31.1 score) and Equal Pay and Opportunity (25.3).
Impact
Cause NPNKF
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company

Nippon Shinyaku

Employees
2,243
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Japan
Share classes
NPNKF
NPPNY
ADR
Description
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. Its Pharmaceuticals Business segment offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases. The company's Functional Food Business segments provides health food ingredients, preservatives, protein preparations, and sports and supplements. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
Material causes
Ethos considers the following causes material for Nippon Shinyaku, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.